ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesGlobeNewsWire • 04/04/24
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/25/24
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseGlobeNewsWire • 03/18/24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024GlobeNewsWire • 03/14/24
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityGlobeNewsWire • 02/29/24
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsGlobeNewsWire • 02/28/24
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionGlobeNewsWire • 02/22/24
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesGlobeNewsWire • 02/14/24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesGlobeNewsWire • 02/07/24
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesGlobeNewsWire • 01/31/24
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's DiseaseGlobeNewsWire • 01/24/24
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain MetastasisGlobeNewsWire • 01/17/24
ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All AccessGlobeNewsWire • 01/10/24
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital MarketsGlobeNewsWire • 01/04/24
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024GlobeNewsWire • 01/03/24
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.GlobeNewsWire • 12/18/23
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200GlobeNewsWire • 12/14/23
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 DiabetesGlobeNewsWire • 12/07/23
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome PathwaysGlobeNewsWire • 12/06/23
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common StockGlobeNewsWire • 11/30/23
